Iron Polymaltose

Iron polymaltose complex delivers ferric iron [Fe³⁺] as a stable, non-ionic macromolecular complex (CAS 53858-86-9, MW ~449 Da) that undergoes controlled active absorption in the duodenum and jejunum via ligand-exchange mechanisms rather than passive diffusion, avoiding the release of free ionic iron that triggers oxidative GI damage. In a randomized trial in pregnant women receiving 200 mg elemental iron daily for 90 days, iron polymaltose raised hemoglobin by 2.16 g/dL versus 1.93 g/dL for ferrous sulfate, demonstrating comparable or superior efficacy with a tolerability profile equivalent to ferrous sulfate across meta-analytic evidence.

Origin & History

Iron polymaltose is a synthetically manufactured macromolecular complex, not derived from any geographic or botanical source. It is produced by combining iron(III) hydroxide [Fe(OH)₃] with polymaltose (a dextrin-derived polysaccharide) under controlled laboratory and pharmaceutical manufacturing conditions. The compound has been developed and commercialized primarily in Europe, Asia, and South America since the 1980s–1990s as a next-generation oral iron preparation designed to minimize the gastrointestinal burden associated with ionic iron salts.

Historical & Cultural Context

Iron polymaltose complex has no roots in ancient herbal or ethnopharmacological traditions; it is entirely a product of modern pharmaceutical chemistry developed in the latter half of the 20th century to address the well-documented tolerability limitations of ferrous sulfate, which had been the standard of care for iron deficiency since the 19th century. The compound was developed and patented primarily by European and South American pharmaceutical firms, gaining widespread clinical use in the 1980s and 1990s under brand names such as Ferrum Hausmann (Vifor Pharma, Switzerland), Maltofer, and others. The rationale for its development drew on fundamental biochemistry research demonstrating that free ionic iron generates hydroxyl radicals via Fenton chemistry in the GI tract, motivating the design of a non-ionic, polymaltose-stabilized ferric complex that would mimic the controlled iron release of endogenous ferritin. Today, iron polymaltose remains listed under ATC code B03AB05 (ferric iron preparations for oral use) and is registered in numerous countries across Europe, Asia-Pacific, and Latin America, though it lacks FDA approval in the United States as a pharmaceutical drug.

Health Benefits

- **Correction of Iron-Deficiency Anemia (IDA)**: Iron polymaltose supplies Fe³⁺ that is absorbed in the duodenum and jejunum, incorporated into ferritin stores, and ultimately utilized for hemoglobin synthesis; clinical trials show hemoglobin increases of up to 2.16 g/dL over 90 days in iron-deficient pregnant women.
- **Reduced Gastrointestinal Tolerability Risk**: Because the complex releases minimal free ionic iron at physiological pH, it does not generate the oxidative mucosal stress or reactive oxygen species responsible for the nausea, constipation, and gastric irritation common with ferrous sulfate, making it suitable for sensitive populations.
- **Controlled, Demand-Driven Absorption**: Active transport mechanisms in enterocytes take up iron from the polymaltose matrix in proportion to the body's iron status, meaning over-absorption is physiologically self-limiting and the risk of acute systemic iron overload from a single therapeutic dose is substantially lower than with ionic salts.
- **Hemoglobin and Ferritin Repletion in Pregnancy**: Supplementation at 100 mg twice daily for 90 days in pregnant women demonstrated statistically significant rises in both hemoglobin and serum ferritin, supporting fetal neurodevelopment and reducing the risk of preterm birth and low birth weight associated with maternal IDA.
- **Pediatric Iron Supplementation**: Iron polymaltose is formulated in palatable syrups, drops, and chewable tablets suited to children; although a meta-analysis found ferrous sulfate numerically superior for hemoglobin and ferritin gains in pediatric IDA, iron polymaltose remains a clinically accepted alternative for children intolerant of ferrous salts.
- **Stability at Neutral pH with Targeted Release**: The complex is chemically stable at intestinal pH (~6–7), protecting against pro-oxidant interactions with dietary components and drugs in the gut lumen, while releasing bioavailable iron at the low pH environment of the duodenal brush border, preserving co-administered nutrient integrity.
- **Support for Oxygen Transport and Energy Metabolism**: Repleted iron supports hemoglobin and myoglobin synthesis, restores cytochrome and oxidative phosphorylation enzyme activity (including cytochrome c oxidase and succinate dehydrogenase), and corrects the fatigue, cognitive impairment, and exercise intolerance characteristic of IDA.

How It Works

Iron polymaltose complex consists of a ferric iron [Fe³⁺] hydroxide core stabilized by a polymaltose carbohydrate shell, forming a structure analogous to ferritin that does not dissociate into free ionic iron at neutral or alkaline pH but releases Fe³⁺ at the low pH (<2–3) of the duodenal microenvironment via a ligand-exchange mechanism involving membrane-bound Fe³⁺ reductases and divalent metal transporter-1 (DMT-1). Upon reduction of Fe³⁺ to Fe²⁺ by duodenal cytochrome b (DcytB) at the apical enterocyte membrane, Fe²⁺ is transported intracellularly via DMT-1; intracellular iron is either stored as ferritin or exported basolaterally via ferroportin-1 (SLC40A1) into portal circulation, where it binds transferrin for delivery to erythroid precursors in the bone marrow. Erythroid uptake is mediated by transferrin receptor-1 (TfR1), after which iron is incorporated into protoporphyrin IX by ferrochelatase to yield heme, which assembles with globin chains to form functional hemoglobin. Systemic iron homeostasis is maintained through hepcidin signaling from the liver: rising serum ferritin and transferrin saturation upregulate hepcidin, which degrades ferroportin and downregulates further absorption, providing an intrinsic safety ceiling absent with passive ionic iron uptake.

Scientific Research

The clinical evidence base for iron polymaltose is moderate in volume and mixed in quality: it includes several randomized controlled trials (RCTs) in pregnant women and children, published absorption studies using neutron-activated tracer methodology, and at least one published meta-analysis. A key absorption study demonstrated only 3.91% ± 2.24% bioavailability for iron polymaltose in iron-depleted volunteers compared to 13.8% ± 6.19% for ferrous ascorbate (p<0.003), though meal-state absorption improved to 3.4–11.9% per day in a subset of patients. A randomized trial in pregnant women (90-day intervention, 200 mg elemental iron/day) showed hemoglobin increments of 2.16 g/dL (polymaltose) vs. 1.93 g/dL (ferrous sulfate), suggesting clinical non-inferiority. A meta-analysis of pediatric IDA trials concluded with moderate-to-high certainty that ferrous sulfate produced superior hemoglobin and ferritin responses compared to iron polymaltose, while finding no significant difference in gastrointestinal side effect rates (high certainty); overall, the evidence supports clinical use but does not establish iron polymaltose as unequivocally superior to ferrous salts across all populations.

Clinical Summary

The most rigorous available evidence—a meta-analysis of pediatric IDA trials rated moderate-to-high certainty—found ferrous sulfate statistically superior to iron polymaltose for hemoglobin and ferritin repletion, with no significant difference in GI adverse event rates. In contrast, an RCT in pregnant women over 90 days (200 mg elemental iron daily) showed iron polymaltose produced a numerically higher hemoglobin increase (2.16 vs. 1.93 g/dL), though sample size details were not fully reported, limiting generalizability. Absorption studies using neutron-activated iron polymaltose measured a mean bioavailability of approximately 3.91% in iron-deficient fasted adults, substantially below that of ferrous ascorbate (13.8%), though food co-administration and vitamin C enhanced absorption. The collective clinical picture supports iron polymaltose as a well-tolerated second-line or alternative therapy for IDA in patients who cannot tolerate ferrous salts, with efficacy that is clinically meaningful though modestly lower than ionic iron forms in certain populations.

Nutritional Profile

Iron polymaltose complex delivers exclusively elemental iron as its active nutrient, with no intrinsic macronutrient, vitamin, or phytochemical content. Each standard pharmaceutical unit provides 50–100 mg elemental iron as Fe³⁺ within the polymaltose matrix (molecular formula C₁₂H₂₅FeO₁₄, average MW 449.163 Da, CAS 53858-86-9). Bioavailability of iron from the complex averages approximately 3.91% under fasted conditions in iron-depleted adults, rising to 3.4–11.9% per day with food and ascorbic acid co-administration; this is substantially lower than ferrous ascorbate (~13.8%) but comparable to or exceeding that of ferrous sulfate in some clinical contexts. Combination products such as Niferex add cofactors critical to erythropoiesis: vitamin C (60–175 mg, enhancing Fe³⁺ reduction), folate as Quatrefolic® (250–1700 mcg DFE, supporting DNA synthesis in erythroid precursors), vitamin B12 (25 mcg, required for normal red blood cell maturation), succinic acid (50–150 mg, facilitating enterocyte-to-bloodstream iron transfer), and zinc (15 mg, supporting immune and enzymatic function).

Preparation & Dosage

- **Film-Coated Tablets**: 100 mg elemental iron per tablet; standard adult dose for IDA is 100–200 mg elemental iron daily (1–2 tablets), taken with or after meals to enhance absorption and minimize GI discomfort.
- **Chewable Tablets**: 50–100 mg elemental iron; used in adults and older children who have difficulty swallowing; can be chewed or dissolved in water.
- **Oral Syrup/Solution**: 10 mg elemental iron per mL (50 mg/5 mL); pediatric dosing typically 3–6 mg/kg/day in divided doses; may be mixed with juice to improve palatability without compromising absorption.
- **Oral Drops**: 50 mg elemental iron per mL; used in infants and toddlers; dose individualized by weight per prescriber guidance.
- **Combination Products (e.g., Niferex Tablets)**: Provide 150 mg elemental iron (ferrous asparto glycinate 50 mg + polysaccharide iron complex 100 mg) plus vitamin C 60–175 mg, folate 1–1.7 mg, vitamin B12 25 mcg, and zinc 15 mg; 1 tablet daily as directed.
- **Timing**: Best absorbed when taken with meals or a small amount of food; vitamin C co-administration (50–200 mg) enhances release and reduction of Fe³⁺ to Fe²⁺; avoid co-administration with antacids, calcium supplements, or bisphosphonates within 2 hours.
- **Treatment Duration**: Typically 3–6 months to normalize hemoglobin and replenish ferritin stores; ferritin should be rechecked at 3 months to assess response.

Synergy & Pairings

Vitamin C (ascorbic acid) at 50–200 mg co-administered with iron polymaltose significantly enhances bioavailability by reducing Fe³⁺ to the more readily absorbed Fe²⁺ form at the duodenal brush border and forming soluble iron-ascorbate chelates that facilitate DMT-1-mediated uptake, as evidenced by improved utilization in clinical absorption studies when the complex is taken with meals containing ascorbic acid. Folate (particularly 5-methyltetrahydrofolate as Quatrefolic®) and vitamin B12 synergize with iron by addressing the co-existing nutritional deficiencies that frequently accompany IDA, ensuring adequate DNA synthesis and red blood cell maturation in erythroid precursors simultaneously with iron repletion. Succinic acid, included in combination formulations, is proposed to facilitate the transfer of absorbed iron from enterocytes to portal blood, complementing the absorptive action of ascorbic acid and potentially improving net iron delivery to erythropoietic tissues.

Safety & Interactions

At therapeutic doses of 100–300 mg elemental iron daily, iron polymaltose exhibits gastrointestinal tolerability statistically equivalent to ferrous sulfate per meta-analytic evidence (high certainty), with reported adverse effects including mild nausea, constipation, dark stools, and abdominal discomfort; the absence of free ionic iron generation at intestinal pH is postulated to reduce mucosal oxidative injury compared to ferrous salts, though this has not been definitively confirmed by head-to-head tolerability RCTs. Key drug interactions include reduced absorption or efficacy of co-administered alendronic acid and other bisphosphonates, aluminium phosphate and aluminium hydroxide antacids (chelation of iron in the GI lumen), and the antipsychotic asenapine (reduced serum levels due to iron-chelation); a minimum 2-hour separation from these agents is recommended. Contraindications include iron overload disorders (hereditary hemochromatosis, hemosiderosis, hemolytic anemias not caused by iron deficiency), known hypersensitivity to any component, and anemias not attributable to iron deficiency; Niferex brand combination products are not FDA-approved, and their safety and efficacy have not been formally established by the FDA. Pregnancy and lactation: iron supplementation is generally recommended in iron-deficient pregnant women; clinical trial data in pregnant women using iron polymaltose at 200 mg/day for 90 days show acceptable safety, but prescribers should confirm diagnosis of IDA before initiating therapy to avoid inadvertent iron excess.